Meeting
2019 Gastrointestinal Cancers Symposium
Alternative chemoradiotherapy to treat locally advanced (LA) anal carcinoma (AC) in patients (pts) with mutations in thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) genes: A case series.
Authors
Wasif M. Saif
Tufts University School of Medicine, Boston, MA
Wasif M. Saif , Ruchi Hamal , Nauman Saleem Siddiqui , Antonia Maloney , Lilian Chen , Kathryn Huber
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 605)
DOI
10.1200/JCO.2019.37.4_suppl.605
Abstract #
605
Poster Bd #
J8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.
First Author: Manabu Muto
Poster
2019 ASCO Annual Meeting
Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase II study with panitumumab (FFCD 0904).
First Author: Thomas Aparicio
Poster
2019 Gastrointestinal Cancers Symposium
Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study.
First Author: Hirva Mamdani
Poster
2018 Gastrointestinal Cancers Symposium
A phase II study of durvalumab following multimodality therapy for locally advanced esophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-ESO14-012 study.
First Author: Hirva Mansurali Mamdani